Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-week Treatment, Randomized, Double-blind, Placebo-controlled, With Open-label Tiotropium, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Patients With Chronic Obstructive Pulmonary Disease

NCT00929110 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00929110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00929110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-week Treatment, Randomized, Double-blind, Placebo-controlled, With Open-label Tiotropium, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Patients With Chronic Obstructive Pulmonary Disease
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2009
Completion date
April 30, 2011
Enrollment
1,066 (actual)
Sites
139

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease